Anticancer Res. 2013 Jan;33(1):261-6.
Phase I Clinical and Pharmacokinetic Study of Bi-weekly Carboplatin/Paclitaxel Chemotherapy in Elderly Patients with Advanced Non-small Cell Lung Cancer.
Tsubata Y, Okimoto T, Miura K, Karino F, Iwamoto S, Tada M, Honda T, Hamaguchi S, Ohe M, Sutani A, Kuraki T, Hamada A, Isobe T.
Source
Department of Internal Medicine, Division of Medical Oncology & Respiratory Medicine, Shimane University Faculty of Medicine, 89-1 Enya-cho, Izumo, Shimane 693-8501, Japan. isobeti@med.shimane-u.ac.jp.
Abstract
Aim: We evaluated the pharmacokinetics and quality of life of elderly patients with advanced non-small-cell lung cancer (NSCLC) treated with bi-weekly carboplatin and paclitaxel chemotherapy, and determined the maximum tolerated dose (MTD) of this treatment.
PATIENTS AND METHODS:
Eligible patients had histologically- or cytologically-proven inoperable NSCLC, age of 70 years or older, no prior treatment, and Eastern Cooperative Oncology Group performance status 0-2. Paclitaxel was administered in combination with carboplatin under a bi-weekly schedule. We determined the plasma concentrations of both drugs during therapy.
RESULTS:
The median patient age was 80 years. Using carboplatin at AUC 3, the MTD of paclitaxel was 100 mg/m(2). Both hematological and non-hematological toxicities were mostly mild and manageable. Although paclitaxel is predominantly metabolized in the liver, clearance was decreased in patients with lower estimated glomerular filtration rate.
CONCLUSION:
Bi-weekly treatment, as described here, is feasible for elderly patients as a conventional regimen, particularly in the outpatient setting, due to its lower toxicity.
No comments:
Post a Comment